Adrenoleukodystrophy Market Insights, Market Outlook and Trends, Epidemiology Insight

DelveInsight's "Adrenoleukodystrophy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Adrenoleukodystrophy Disease Understanding and Treatment Algorithm

Adrenoleukodystrophy Overview

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. Currently, no drug is approved for the treatment of Adrenoleukodystrophy and the available treatment options include hormone replacement therapy, dietary therapy with Lorenzo’s oil and Hematopoietic stem cell transplantation, using either umbilical cord or bone marrow stem cells.

Adrenoleukodystrophy Diagnosis 

The diagnosis of Adrenoleukodystrophy is difficult as its symptoms are similar to other diseases such as attention deficit hyperactivity disorder, epilepsy, autism, and other learning disabilities. The diagnosis is done by the use of diagnostic assays, imaging tests, adrenal function testing, and prenatal diagnosis. In recent years various countries started the newborn screening programs to identify the conditions that may affect a baby’s long-term health and survival. The newborn screening programs also included the screening of Adrenoleukodystrophy and gained huge success in early detection and cost-saving.

Adrenoleukodystrophy Treatment 

The DelveInsight Adrenoleukodystrophy market report gives a thorough understanding of Adrenoleukodystrophy by including details such as disease definition, clinical aspects, symptoms, causes, inheritance pattern, pathophysiology, and diagnosis. It covers the details of conventional and current medical therapies available in the Adrenoleukodystrophy market for the treatment of the condition. It also provides treatment guidelines for Adrenoleukodystrophy in the US and Europe. 

Adrenoleukodystrophy Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Adrenoleukodystrophy in the 7MM, Gender-specific Prevalence of Adrenoleukodystrophy in the 7MM, Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the 7MM, and Type-specific Diagnosed Prevalence of ALD in Males in the 7MM. The epidemiology section covers the 7MM countries, the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from the year 2017 to 2030.  

Adrenoleukodystrophy Drug Chapters

Lenti D: Bluebird Bio

Lenti D is an investigational gene therapy that is in Phase II/III stage of development for the treatment of cerebral ALD (CALD). Currently, bluebird bio is enrolling patients for a Phase III study (ALD-104) designed to assess the efficacy and safety of Lenti-D after myeloablative conditioning using busulfan and fludarabine in patients with CALD. Additionally, the company is conducting a long-term safety and efficacy follow-up study (LTF-304) for patients who have participated in ALD-102 and were treated with Lenti-D.

Leriglitazone: Minoryx Therapeutics, S.L.

Leriglitazone (MIN-102) is a metabolite of pioglitazone which shows an excellent brain penetration and safety profile, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. The drug candidate is in Phase II/III stage of development for the treatment of both cerebral ALD and Adrenomyeloneuropathy (AMN).

Products detail in the report…

Adrenoleukodystrophy Market Outlook

The Adrenoleukodystrophy market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Adrenoleukodystrophy market trends by analyzing the impact of current and emerging therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to DelveInsight, Adrenoleukodystrophy market in 7MM is expected to change in the study period 2017–2030.

Key Findings

This section includes a glimpse of the Adrenoleukodystrophy market in the 7MM.

The United States Market Outlook

This section provides the total Adrenoleukodystrophy market size and market size by therapies in the United States. 

The market size for ALD was USD 523.26 million in 2017. DelveInsight’s analysts estimate that the market is expected to experience a significant rise in the coming years. Although, a noticeable growth can be seen in the year 2022 owing to the launch of Lenti-D (Gene therapy; Bluebird Bio), and Leriglitazone (MIN-102) (Minoryx Therapeutics).

EU-5 Countries: Market Outlook

The total Adrenoleukodystrophy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook 

The total market size of Adrenoleukodystrophy in Japan was USD 103.58 million in 2017.

Adrenoleukodystrophy Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Adrenoleukodystrophy key players involved in developing targeted therapeutics. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Adrenoleukodystrophy emerging therapies

Request for free sample pages: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market

Reimbursement Scenario in Adrenoleukodystrophy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 

Some Frequently Asked Questions

What is Adrenoleukodystrophy (ALD)? 

Adrenoleukodystrophy (ALD) is a rare, X-linked, genetic disorder in which mutations within the ABCD1 gene lead to the loss of function of adrenoleukodystrophy protein (ALDP).

How many therapies or drugs are in the Adrenoleukodystrophy (ALD) pipeline?

Major upcoming products mainly include Lenti-D (Genetherapy; Bluebird Bio), MIN-102 (Minoryx Therapeutics), OP-101 (Orpheris), and MD1003 (MedDay Pharma) in the ALD market.

Which geography accounted for the largest Adrenoleukodystrophy (ALD) market size?

The United States accounts for the largest market size of Adrenoleukodystrophy (ALD), as well as, Cerebral Adrenoleukodystrophy (CALD), in comparison to EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

What was the Adrenoleukodystrophy (ALD) total prevalence in 7 the major markets?

Total Adrenoleukodystrophy (ALD) Prevalent cases of in 7 major markets was estimated to be approximately 27,011 in 2017.

Which are the leading companies in Adrenoleukodystrophy (ALD) market?

Key companies like BlueBird Bio, MedDay Pharmaceuticals, Minoryx Therapeutics, Neurovia Inc., and Orpheris Inc. Pharmaceuticals have focussed on developing therapies for the treatment of ALD.

Which therapy is expected to grab the maximum share in Adrenoleukodystrophy (ALD) market during the study period 2017-30?

Lenti-D (Bluebird Bio), gene therapy shall prove to be blockbuster and shall account for the majority of the market share amongst all the upcoming therapies.

Download free sample pages of the report: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market